ABSTRACT
INTRODUCTION
One of the most popular uses of DNA microarrays is the comparison of differences in gene expression under two distinct experimental conditions (treated vs. untreated samples, diseased vs. normal tissue, mutant vs. wild-type organisms, etc) (Breitling, et al., 2004) . In this type of experimental setup, a major challenge is the identification of those genes whose expression is significantly different between two conditions (Aittokallio, et al., 2003) . Many sophisticated statistical methods have been tested, in attempts to achieve a more reliable identification of differentially regulated genes (Huber, et al., 2002; Irizarry, et al., 2003; Yang, et al., 2001; Yang, et al., 2002) . In fact, many of the existing statistical methods for microarray analysis have been developed by using data sets, in which changes in gene expression are abundant, * To whom correspondence should be addressed.
with many genes having a high magnitude of change that far exceeds the observed variability in expression (Ramaswamy, et al., 2001) .
However, for many physiological and metabolic conditions, the changes in gene expression are often moderate compared to the array-wide variability in expression, thus leading to modest p values, such that existing statistical models often miss most of the real changes (Mootha, et al., 2003) .
We therefore sought to develop an analytical approach that provides experimental biologists with a more thorough understanding of the statistical significance of any list of genes produced under conditions where the real changes are of modest magnitude but the expressional level is still high in both experimental conditions. An important issue is associated with the normalization of the relative expression of genes across a series of microarray experiments (Colantuoni, et al., 2002) . The normalization across arrays has been extensively used to minimize systematic variations in specific samples Gautier, et al., 2004; Huber, et al., 2002; Irizarry, et al., 2003; Yang, et al., 2002) . The selection of appropriate controls for normalization has been proposed for comparisons of expression levels across samples (Yang, et al., 2002) . A set of controls (microarray sample pool) with minimal sample-specific bias over a large intensity range was introduced to aid in intensity-dependent normalization. In Affymetrix GeneChip arrays, each gene is represented by a set of 11-20 pairs of probes (perfect match and a mismatch), and the intensities for each probe set is summarized by the log scale robust multi-array analysis (RMA) . It has been reported (Li and Wong, 2001 ) that variation of a specific probe across multiple arrays could be considerably smaller than the variance across probes within a probe set. RMA method effectively accounted for this strong probe affinity effect, and consequently improved the ability to detect differentially expressed genes between samples.
Since using multiple arrays for normalization had improved the detection of differentially expressed genes between samples, we attempted a further development on gene-specific, multi-array standardization method using a large collection of expression data available from the public database. Our focus was to better understand the biological relevance of detected difference of gene expression, rather than improving the fluorescence intensity normalization that many of existing methods (for example, RMA method) focused on. With the rapid increase of microarray expression data in the public database over the past few years, it has become possible to monitor the general expression level of a Associate Editor: Joaquin Dopazo gene in diverse biological samples under various conditions. Through the creation of the database-wide expression profile for individual genes (or probesets), which allows an estimation of the gene-specific distribution of expression level in various experimental conditions, it is possible to standardize individual gene expression intensities in a specific assay by using their unique database-wide means and standard deviations. This consideration of gene's behavior in a wide variety of biological conditions gives us new insight on interpreting the expressional difference between given samples. In a biological point of a view, the expressional difference of a gene with a small DB-wide expressional variation should have more attention than those with large DB-wide variations. Retrieving a large amount of expression data available in the public database, NCBI GEO (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo) (Barrett, et al., 2005) , we developed a web-based computational tool to apply GEO-wide means and standard deviations to re-standardizing individual gene expression levels in specific samples. The organization of gene expression data in GEO are schematically presented in Figure 1 . Submitted samples are assembled into biologically meaningful and statistically comparable GEO DataSets (GDS). Samples within a GDS refer to the same platform, that is, a common set of elements are assayed. Each individual entity is assigned a unique and stable accession number; the accession number prefix indicates whether the record is a GEO Platform (GPL), Dataset (GDS), or Sample (GSM). GEO is the largest fully public repository for gene expression data. It currently holds over 70,000 sample data (GSMs) generated from more than 2,000 different DNA chips (GPLs). Geo samples indicated by bold letters were analyzed in this study. GSM2240 and GSM21241 were generated with normal epithelial cells. GSM21239 and GSM21238 are from a breast cancer cell line, HCC1954. The GEO platform GPL91 includes a total of 73 data sets (GDSs). GDS817 includes 6 GSMs, four of which were comparatively analyzed in this study. GPL91 includes 1,850 GSMs in total. It is assumed that the gene expression data in the GEO database are deposited after log ratio transformation for dual channel data and log (signal -background) transformation for single channel data. We tried to re-standardize single channel data based on the GEO-wide normal distribution model, N(μ GPL , σ GPL ) where the mean (μ GPL ) and standard deviation (σ GPL ) of a gene were calculated from all the available expression data of the gene sharing the same GEO platform (i.e., DNA chip). This approach provides a unique gene-specific standardization based on the expression distribution of the gene in a collection of GDSs sharing the same platform. Data from dual channel experiments do not allow GEO-wide mean expression levels and standard deviations to be calculated for individual genes, since the deposited expression data is in the form of a ratio (R/G ratio) between a test and a reference set. Thus, the focus of this study was on the analysis of log(background-subtracted signal intensity) data from single channel experiments.
In order to calculate means and standard deviations from a large collection of heterogeneous datasets (GDSs), the individual array data must be locally standardized in advance to achieve a common scale. Thus, in practice, we attempted a two step standardization procedure for single channel microarray data. Within-array standardization (array-specific z-score calculation) was followed by the gene-specific multi-array standardization using the GEOwide mean and standard deviation of individual genes (genespecific z-score calculation). For the demonstration, a GEO Dataset (GDS) including samples of normal cells and a breast cancer cell line was analyzed by the present two step procedure. The possibility of obtaining meaningful information from the second step gene-specific standardization was investigated in comparison with the result from the one-step array-specific standardization. The second step standardization intrinsically prioritizes genes which have small expressional variations in the database (small σ GPL ). Although the differential expression of a gene which has a large database-wide variation (large σ GPL ), may be underestimated by the present method, it is typically well recognized by conventional methods such as direct t-tests and ranking tools provided from the GEO website. In this sense, the present method will be complementary to existing analytical tools, and thus contribute to maximize the utility of gene expression data deposited in the public database.
METHODS

Microarray gene expression data acquisition
Microarray gene expression data were obtained from the Entrez Gene Expression Omnibus (GEO) ftp site (ftp.ncbi.nlm.nih.gov/pub/geo) (Barrett, et al., 2005; Edgar, et al., 2002) . A set of single channel microarray data on normal and breast cancer cell lines were analyzed for the demonstration. The GEO accession number, GDS817 which includes 6 samples (GSMs) is a collection of microarray experiments for the comparison of gene expression between breast cancer and normal epithelial cell lines (Figure 1 ). The two samples in GDS817 are experiments done with the breast cancer cell line, HCC622. Another two involve a normal epithelial cell line. We analyzed the difference in gene expression between these two types of cell lines. The GDS817 experiments were carried out with the Affymetrix U95A DNA chip (GEO accession number GPL91) which includes a total of 12,651 probesets. GDS817 contains expression data records for only 12,625 probesets. Thus, our analysis was limited to this subset of probesets in GPL91. In addition to GDS817, a total of 72 additional GDSs sharing a common platform, GPL91, were retrieved from the current version of GEO for the gene-specific GEO-wide standardization procedure. In summary, expression data for 12,625 genes in a total of 1,850 GSMs from 73 GDSs which share a common platform, GPL91, were retrieved and analyzed in this study.
Gene Specific Large-scale Analysis of Gene Expression (GS-LAGE)
It is a standard practice to correct for foreground intensities by background subtraction (Edwards, 2003) . For single channel experiment data deposited in GEO, it is assumed that the values were submitted as normalized (scaled) signal count data (for example, log (signal -background) transformation). However, in order to calculate the mean and standard deviation of the expression level of a gene using a large collection of datasets (GDSs) that were prepared and deposited by different research groups, the individual array data from GEO needed to be re-standardized to achieve a common scale. Thus, we first carried out within-array ztransformation on each of all collected GEO samples by using the mean expression level and its standard deviation on the array basis, as below. μ GSM : the mean expression level of all genes in the given GSM. σgsm: the standard deviation of all genes in the given GSM.
ui is the standardized intensity of the ith gene in the given GSM. This GSMbased standardization process was repeated for all 1,850 GSMs sharing the GPL91 platform, to permit comparisons between samples to be made. We next calculated the mean expression level and its standard deviation of each gene across arrays using the z-transformed expression data from 1,850 GSMs. μi,GPL is thus the GPL-wide mean of ith gene. The z-transformed expression level (ui) in a specific assay (GSM) was next re-scaled by the model established from the GPL-wide mean and standard deviation. The expression level, v i , of a gene thus represents the re-scaling based on the observation of its expressional behavior in a large collection of diverse experiments. It is assumed that the expressional variation of a gene in the database follows the normal disbrition, N(μi,GPL, σi,GPL) when n is large. To confirm this assumption, we implemented an iterative procedure to remove outliers from the final μi,GPL and σi,GPL calculations. An outlier was defined as an expression level of which distance to the original μGPL is three times greater or smaller than the original σGPL. Then, final μi,GPL and σi,GPL values were used for chi square goodness of fit test between observed distribution and its ideal normal distribution. Genes whose expressional variation is significantly deviated from normal distribution (P<0.05 in the chi square test) were removed from the second standardization (v calculation).
In this study, we compared u i and v i in identifying changes in gene expression between normal and breast cancer cells. ui is assumed to be a quantity provided by the original contributor, which only considers the expression data within the GDS for the preparation. The difference in normalized gene expression between normal and breast cells was calculated as below. 
Validation using an Affymetrix spike-in study data set
For the validation study, a dataset from the spike-in study by Affymetrix was retrieved from Affycomp website (http://affycomp.biostat.jhshp.edu/). In this dataset, Human cRNA fragments matching 16 probe-sets on the HGU95A GeneChip were added to the hybridization mixture of the arrays at concentrations ranging from 0 to 1024 picoMolar. The same hybridization mixture, obtained from a common tissue source, was used for all arrays. The details of the spike-in data are found in the literature Irizarry, et al., 2003) and the website (http://affycomp.biostat.jhsph.edu/). The fluorescence intensities were normalized by RMA method. These RMA data were used for further analysis by the present two-step standardization method after log2 transformation.
Gene expression data analysis by GEO-provided tools
For comparison with the present method, we also analyzed the gene expression data between breast cancer and normal cell lines using GEOprovided analytical tools. Three methods were used to generate lists of probesets which showed significant higher expression levels in the breast cancer cell line than the normal epithelial cell line. The options were appropriately selected as below to include similar number of entries in the final lists. Here, "A" represents gene expression data on the breast cancer cell line (HCC1954) and "B" represents gene expression data on normal epithelial cell line. 1. One-tailed t-test (A>B) (0.010 significance level) selected a total of 254 probesets. 2. Query mean group A vs B by values (4-fold higher ) selected a total of 266 probesets. 3. Query mean group A vs B by ranks (3-fold higher) selected a total of 204 probesets.
RESULTS
Since the downloaded data for the demonstration were the normalized and combined Affymatrix data from GEO (GPL91), the MA plot of test samples from GDS817 was already in a good shape (Figure 2A ). The present two-step standardization procedure was applied to these data sets in order to achieve a better resolution in detecting the modest expressional difference in genes with relatively small DB-wide standard deviation, σ GPL . We first carried out within-array z-transformation on each of all collected samples by using the mean expression level and its standard deviation on the assay basis. The resulting scatter plot ( Figure 2B ) is basically same as the MA plot (Figure 2A) . After the first step, array-specific standardization, the difference in gene expression between normal and cancer cells showed a symmetrical distribution along the diagonal axis ( Figure 2B ). After u+ and uare re-scaled via gene-specific normal distribution, i.e. N(μ i,GPL, σ i,GPL ) for the i th gene, the relatively large deviation in gene expression between normal and breast cancer cells were shifted to the high intensity region ( Figure 2C ). This observation suggests that genes with large µ i,GPL have more variation in σ GPL than those with small µ i,GPL .
To further investigate the difference between Figure 2B and 2C, we plotted the mean (μ GPL ) and standard deviation (σ GPL ) of each gene expression in 1,850 experiments (Figure 3 ). These mean and standard deviation were used for the second standardization (v calculation). It has been well recognized that the variance of the measured spot intensities increases with their mean. The standard deviation increases roughly linearly with the mean (Huber, et al., 2002) . The present plot of the DB-wide analysis also indicates that expressional variation (i.e. σ GPL in the plot) is increased as μ GPL increase. In addition, the plot shows that the vertical distribution of σ GPL becomes wider as the μ GPL increases. This relatively large variation in σ GPL values in the high μ GPL region contributed to the difference of the plot shape between Figure 2B and 2C. For a given μ GPL value, a large σ GPL resulted in a small v value, while a small σ GPL value resulted in a large v in the second standardization.
This analysis confirms that the present model, based on N(μ i,GPL, σ i,GPL ) provides an additional resolution particular to recognizing the expressional difference of genes with relatively small σ GPL and high expressional intensity, i.e., large μ GPL . Figure 3 . Gene-specific mean intensity and its standard deviation. The mean and standard deviation of up to 1,850 expressions for a gene was calculated using all the standardized expression data (u) of the given gene in the same platform, GPL91, found in GEO database. A total of 10,792 genes were plotted. However, a small number of genes with a mean of >1.5 were omitted in this plot, to achieve a better resolution on the area of major distribution. Figure 2A and 2B shows that the single step standardization actually represents the original normalization of Affymetrix GeneChip data.
However, the second step standardization generated a substantial shift in the distribution from that of single step standardization of gene expression. From a biological point of view, a large expressional change between specific samples for a gene which has a large σ GPL may be less meaningful than a moderate expressional change for a gene having a consistent expression in the database (low σ GPL ). Typical array-specific standardization and a consequent comparison of the intensity of gene expression between samples lack this kind of biological consideration. In this sense, our two-step analysis provides a unique tool for identifying additional genes with moderate changes between samples that are not highly prioritized by conventional assay-specific standardization methods. We compared the performance of the two methods (i.e., Δu' vs. Δv' scorings) in evaluating differences in gene expression between normal and breast cancer cells ( Figure 4A ). A significant number of genes with low and high expression levels were evaluated differently by these two methods. The result shows that the utility of two step standardization method is on identifying those genes in which the difference of expression between samples is underestimated by the single step, array-specific standardization method. On the upper boundary region of the distribution shown in Figure 4A , the Δv' calculation gives up to two-fold higher estimation than the Δu' calculation for gene expression difference between samples. Among 10,792 test genes from GPL91, 90.5% showed the discrepancy of less than 1.0 between two methods (i.e., |Δv'-Δu'|<1.0), while 9.5% of genes showed the discrepancy of greater than 1.0 ( Figure 4B ). 2.4% of genes showed the discrepancy of greater than 2.0 between two methods. We also compared the result of the present method with that of RMA method. RMA method is developed for better normalization of fluorescence intensity data by accounting for probe affinity effect, while our present method is for providing better biological insight on interpreting the expressional difference of genes in the database that are assumed to have already been properly normalized. We thus applied the present method to the data that were already normalized by RMA method. For this comparative analysis, a dataset from the spike-in study by Affymetrix was used. Human cRNA fragments matching 16 probe-sets on the HGU95A GeneChip were added to the hybridization mixture of the arrays at concentrations ranging from 0 to 1024 picoMolar. The same hybridization mixture, obtained from a common tissue source, was used for all arrays (See Methods section for details). The fluorescence intensity data were normalized by RMA method, and then the present two-step method was applied to the normalized data. Observed concentrations are comparatively plotted against nominal concentration ( Figure 5 ). In this analysis, the observed intensities are averaged at each nominal concentration value, resulting in a single mean curve. Since the log 2 scale was applied to the concentrations, observed concentrations should be linear in true concentrations. We therefore fit a simple linear model to the scatterplot data and report the R 2 coefficient. The result shows that the present two-step standardization (LAGE) data has a similar R 2 coefficient with the original RMA data. This confirms that the additional standardization by N(μ GPL, σ GPL ) does not change the linearity of the original data. However, the rank order of test genes by observed differential expressions (∆v' and ∆RMA) between samples showed a large disagreement between the present method and RMA method (Table 1 ). When expressional difference between samples was compared among 14 genes, the RMA method provided a more consistent performance than the present method. These 14 test genes showed large variations in their µ GPL and σ GPL values. The variation in ∆RMA among 14 genes is random, i.e. no correlation with their σ GPL . However, our present method gives additional weights to the expressional difference of those genes (for example, 407_at) that have relatively small σ GPL , while it give a low significance on the expressional difference of genes with a large σ GPL (for example, 33818_at). We believe that this σ GPL -dependent prioritization of gene expression difference improves the identification of previously unknown disease-related genes from database search. For a demonstration of the usefulness of the present method, we compared the performance of the two-step method with those methods provided by GEO website (See Methods section for the detail) in evaluating differences in gene expression between normal and breast cancer cells. A total of 10,791 probesets were first ranked based on the Δv' score. Then, a total of 100 topranked probesets were investigated if they were also prioritized by GEO-provided analytical methods. As a result, 22 probesets on the top-ranking list on the Δv' score were unique and not found in the GEO analysis reports, while 78 probesets were found in both Δv'-ranking list and GEO anslysis reports (Table 2 ). These two sets of genes (un-overlapped and overlapped with GEO lists) commonly showed relatively low μ GPL and σ GPL in comparison with those of total 10,791 probesets in GPL91. However, the un-overlapped set Table 3 . Cancer-related genes exclusively identified by the present Δ Δ Δ Δv'-scoring method. Among the top100 probesets ranked based on Δv' score, a total of 22 probesets were unoverlapped with the selections by GEO analyses (See the method section for the detailed procedure of GEO analyses). The listed genes represents 12 probesets which shows a large rank discrepancy between Δu' and Δv'.
A total of 22 probesets (actually 20 different genes) that were exclusively found in the top-ranking list by the two-step method needed to be further analyzed to determine if there are breast cancer-related genes that were not identified by GEO analysis reports. A subset of 12 probsets that showed large difference in the ranking between Δu' and Δv' are listed (Table 3) . From a literature search, we found that 3 of these 12 genes were specifically elevated in cancer-related cells. For exmaple, the MRE11 (gene ID: AF073362) -Rad50-NBS1 complex is a cell cycle check point protein and tumor cells have defects in the cell cycle check point protein. It has been known that two components of the MRE11-Rad50-NBS1 complex, RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability (Heikkinen, et al., 2006) and the MRE11 gene is mutated in an ataxia-telangiectasia-like disorder (Stewart, et al., 1999) . Insufficient information was available to determine if other 9 genes exclusively found on the top ranking list of Δv' scoring are associated with breast cancer pathogenesis in the current NCBI database. Table 3 shows that the difference of expressional intensity between normal and breast-cancer cell lines for these genes was estimated to be at least 1.5-fold higher in Δv' measure than in Δu' measure. It can be concluded that relatively low σ GPL values compensate the moderate difference in expression between samples and consequently rank genes in a different order. Further experimental study remains to confirm the association of the selected 9 genes with breast tumors.
The relative merit of the present method depends on its ability to successfully identify genes that are differentially expressed, while avoiding classifying highly fluctuating genes (i.e, genes with large σ GPL ) as being differentially expressed (i.e., their false positive or Type I Error rate). Since the false positive rate increases exponentially as the rank goes to the bottom (Norris and Kahn, 2006) , medium-level fold changes (moderate Δu') in gene expression were usually not considered for further experimental validation. In this sense, this new approach can enrich the hit list of genes in which expression difference between normal and breast cancer cells were moderate. For public access to this two-step standardization method for GEO gene expression data, we constructed a user friendly webbased database, GS-LAGE (Gene Specific Large-scale Analysis of Gene Expression) which includes all single channel microarray experiments listed on the GEO database ( Figure 6 ). It can be accessed via http://compbio.sookmyung.ac.kr/~lage/index.html. It provides comparative values of Δu' and Δv' for each gene between user-selected experimental samples. It will provide a valuable tool for the in silico identification of previously unknown specific (or differential) gene expression patterns in disease-related samples.
